Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
作者信息
Marinoni Ilaria
机构信息
Pathology, University of Bern, Bern, Switzerland
出版信息
Gut. 2022 May;71(5):847-848. doi: 10.1136/gutjnl-2021-324664. Epub 2021 May 11.
Abstract
摘要
相似文献
1
Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?DAXX/ATRX表达缺失和ALT激活在胰腺神经内分泌肿瘤中的预后价值：是时候进行临床应用了吗？
Gut. 2022 May;71(5):847-848. doi: 10.1136/gutjnl-2021-324664. Epub 2021 May 11.
2
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.无功能性胰腺神经内分泌肿瘤：ATRX/DAXX 和端粒的非经典延长（ALT）与 ARX/PDX1 表达和肿瘤大小无关，具有独立的预后价值。
Gut. 2022 May;71(5):961-973. doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13.
3
Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.胰腺神经内分泌肿瘤中 ATRX/DAXX 基因改变的预后意义：一项荟萃分析。
Front Endocrinol (Lausanne). 2021 Jun 18;12:691557. doi: 10.3389/fendo.2021.691557. eCollection 2021.
4
Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).原文重现：将 DAXX、ATRX 和端粒的替代性延长（ALT）纳入胰腺神经内分泌肿瘤（PanNETs）评估中的诊断和预后效用。
Hum Pathol. 2023 Feb;132:1-11. doi: 10.1016/j.humpath.2023.01.004. Epub 2023 Jan 24.
5
Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.内镜超声引导下细针活检评估无功能胰腺神经内分泌肿瘤中 DAXX/ATRX 表达和端粒的非经典延长状态。
Pancreatology. 2023 Jun;23(4):429-436. doi: 10.1016/j.pan.2023.05.002. Epub 2023 May 5.
6
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.在胰腺神经内分泌肿瘤的细针穿刺抽吸活检（FNA）中可可靠检测到端粒的替代性延长以及ATRX/DAXX缺失。
Cancer Cytopathol. 2017 Jul;125(7):544-551. doi: 10.1002/cncy.21857. Epub 2017 Apr 3.
7
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.端粒替代延长及DAXX/ATRX表达缺失预示胰腺神经内分泌肿瘤患者发生转移性疾病及生存不良。
Clin Cancer Res. 2017 Jan 15;23(2):600-609. doi: 10.1158/1078-0432.CCR-16-1113. Epub 2016 Jul 12.
8
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.DAXX/ATRX基因和MEN1基因是胰腺神经内分泌肿瘤的重要预后标志物。
Oncotarget. 2017 Jul 25;8(30):49796-49806. doi: 10.18632/oncotarget.17964.
9
The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.将 DAXX、ATRX 和端粒的非经典延长纳入到胰腺神经内分泌肿瘤的评估中，对其诊断和预后具有重要意义。
Hum Pathol. 2022 Nov;129:11-20. doi: 10.1016/j.humpath.2022.07.015. Epub 2022 Jul 21.
10
Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity.胰腺神经内分泌肿瘤中 ATRX 和 DAXX 的缺失：与复发风险、细胞表型和异质性的关联。
Hum Pathol. 2024 Aug;150:51-57. doi: 10.1016/j.humpath.2024.06.015. Epub 2024 Jun 21.
引用本文的文献
1
Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy.解读胰腺神经内分泌肿瘤：分子特征、生物标志物及个性化治疗途径
Int J Mol Sci. 2025 Aug 13;26(16):7814. doi: 10.3390/ijms26167814.
2
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective.从生物标志物和手术角度看小胰腺神经内分泌肿瘤患者的管理
Endocr Relat Cancer. 2025 Apr 4;32(5). doi: 10.1530/ERC-24-0305. Print 2025 May 1.
3
Generation of an Obese Diabetic Mouse Model upon Conditional Disruption.条件性破坏后肥胖糖尿病小鼠模型的建立。
Cancers (Basel). 2023 Jun 1;15(11):3018. doi: 10.3390/cancers15113018.
4
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer.染色质重塑因子ATRX：在生物学和癌症中的作用及机制
Cancers (Basel). 2023 Apr 10;15(8):2228. doi: 10.3390/cancers15082228.
5
Somatostatin receptor activity assessed by Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors.通过 Ga-DOTATOC PET 评估生长抑素受体活性可以术前预测高分化胰腺神经内分泌肿瘤中 DAXX/ATRX 的表达缺失。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2818-2829. doi: 10.1007/s00259-023-06210-7. Epub 2023 Apr 3.
6
Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).原文重现：将 DAXX、ATRX 和端粒的替代性延长（ALT）纳入胰腺神经内分泌肿瘤（PanNETs）评估中的诊断和预后效用。
Hum Pathol. 2023 Feb;132:1-11. doi: 10.1016/j.humpath.2023.01.004. Epub 2023 Jan 24.
7
An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs.不同消化器官神经内分泌肿瘤的概念发展、诊断标准及挑战性问题的最新进展
Virchows Arch. 2022 Jun;480(6):1129-1148. doi: 10.1007/s00428-022-03306-7. Epub 2022 Mar 12.
8
Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).神经内分泌肿瘤的诊断、预测和预后标志物研究进展（综述）
Exp Ther Med. 2021 Dec;22(6):1479. doi: 10.3892/etm.2021.10914. Epub 2021 Oct 25.
本文引用的文献
1
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.无功能性胰腺神经内分泌肿瘤：ATRX/DAXX 和端粒的非经典延长（ALT）与 ARX/PDX1 表达和肿瘤大小无关，具有独立的预后价值。
Gut. 2022 May;71(5):961-973. doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13.
2
Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.胰腺神经内分泌肿瘤的表观遗传学景观揭示了不同的起源细胞和肿瘤进展的方式。
Commun Biol. 2020 Dec 7;3(1):740. doi: 10.1038/s42003-020-01479-y.
3
Surgical Management of Neuroendocrine Tumours of the Pancreas.胰腺神经内分泌肿瘤的外科治疗
J Clin Med. 2020 Sep 16;9(9):2993. doi: 10.3390/jcm9092993.
4
Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.端粒的替代性延长和内分泌转录因子的差异表达可区分转移性和非转移性胰岛素瘤。
Endocr Pathol. 2020 Jun;31(2):108-118. doi: 10.1007/s12022-020-09611-8.
5
Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.全基因组测序揭示了胰岛素瘤和无功能性胰腺神经内分泌肿瘤的不同遗传基础：导致了一个新的分类系统。
Gut. 2020 May;69(5):877-887. doi: 10.1136/gutjnl-2018-317233. Epub 2019 Aug 28.
6
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.增强子特征可对无功能胰腺神经内分泌肿瘤的结局进行分层和预测。
Nat Med. 2019 Aug;25(8):1260-1265. doi: 10.1038/s41591-019-0493-4. Epub 2019 Jul 1.
7
Whole-genome landscape of pancreatic neuroendocrine tumours.胰腺神经内分泌肿瘤的全基因组图谱。
Nature. 2017 Mar 2;543(7643):65-71. doi: 10.1038/nature21063. Epub 2017 Feb 15.
8
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.原发性胰腺神经内分泌肿瘤中端粒的替代性延长与侵袭性临床行为及不良生存相关。
Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.
9
Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.DAXX 和 ATRX 的缺失与染色体不稳定性和胰腺神经内分泌肿瘤患者的生存降低有关。
Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.
10
Altered telomeres in tumors with ATRX and DAXX mutations.肿瘤中 ATRX 和 DAXX 突变导致端粒改变。
Science. 2011 Jul 22;333(6041):425. doi: 10.1126/science.1207313. Epub 2011 Jun 30.
Zotero 插件